E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 4/2/2020 in the Prospect News Structured Products Daily.

New Issue: Citigroup prices $500,000 barrier securities on linked to three stocks

By Sarah Lizee

Olympia, Wash., April 2 – Citigroup Global Markets Holdings Inc. priced $500,000 of 0% barrier securities due Sept. 30, 2021 linked to the worst performing of the common stocks of Johnson & Johnson, Pfizer Inc. and UnitedHealth Group Inc., according to a 424B2 filing with the Securities and Exchange Commission.

The notes are guaranteed by Citigroup Inc.

The payout at maturity will be par plus 3 times the worst performing stock if all three underliers finish above their initial level.

If the worst performer declines, but not more than 25%, the payout at maturity will be par.

Otherwise, investors will be fully exposed to the decline of the worst performing stock.

Citigroup Global Markets Inc. is the underwriter.

Issuer:Citigroup Global Markets Holdings Inc.
Guarantor:Citigroup Inc.
Issue:Barrier securities
Underlying stocks:Johnson & Johnson, Pfizer Inc. and UnitedHealth Group Inc.
Amount:$500,000
Maturity:Sept. 30, 2021
Coupon:0%
Price:Par
Payout at maturity:Par plus 3 times return of worst performing stock; par if worst performer declines, but not more than 25%; otherwise full exposure to decline of worst performer
Initial stock levels:$119.18 for Johnson, $29.70 for Pfizer, $219.80 for UnitedHealth
Barrier levels:$89.385 for Johnson, $22.275 for Pfizer, $164.850 for UnitedHealth; 75% of initial levels
Strike date:March 24
Pricing date:March 25
Settlement date:March 30
Underwriter:Citigroup Global Markets Inc.
Fees:0.3%
Cusip:17328VC24

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.